METASPACEX (01796) Enters Strategic Cooperation Agreement with Xinhua Pharmaceuticals

Stock News12-10

METASPACEX (01796) announced that on December 10, 2025, the company signed a strategic cooperation agreement with Xinhua Pharmaceutical Development (Qianjiang) Co., Ltd.

Under the agreement, both parties have initially agreed to explore collaborative opportunities in China's traditional Chinese medicine (TCM) and healthcare industry. To capitalize on policy opportunities and market growth potential in the TCM and healthcare sectors, the two companies intend to establish strategic partnerships in areas including TCM resource development, production and supply chain management, modern TCM product R&D, manufacturing, marketing, as well as capital market and industrial cooperation.

The strategic cooperation aims to achieve complementary resources and synergistic development. Both parties will also engage in in-depth collaboration by integrating big data and advanced intelligent computing to focus on AI-driven standardization, modernization, and marketing of TCM.

Depending on market conditions and cooperation progress, senior management meetings may be held periodically to discuss the form, direction, and other relevant matters regarding collaborative projects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124640871?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124640871","market":"hk","top_or_hot":-1,"title":"METASPACEX (01796) Enters Strategic Cooperation Agreement with Xinhua Pharmaceuticals","media":"Stock News","content":"<p>METASPACEX (01796) announced that on December 10, 2025, the company signed a strategic cooperation agreement with Xinhua Pharmaceutical Development (Qianjiang) Co., Ltd.</p>\n<p>Under the agreement, both parties have initially agreed to explore collaborative opportunities in China's traditional Chinese medicine (TCM) and healthcare industry. To capitalize on policy opportunities and market growth potential in the TCM and healthcare sectors, the two companies intend to establish strategic partnerships in areas including TCM resource development, production and supply chain management, modern TCM product R&D, manufacturing, marketing, as well as capital market and industrial cooperation.</p>\n<p>The strategic cooperation aims to achieve complementary resources and synergistic development. Both parties will also engage in in-depth collaboration by integrating big data and advanced intelligent computing to focus on AI-driven standardization, modernization, and marketing of TCM.</p>\n<p>Depending on market conditions and cooperation progress, senior management meetings may be held periodically to discuss the form, direction, and other relevant matters regarding collaborative projects.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>METASPACEX (01796) Enters Strategic Cooperation Agreement with Xinhua Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMETASPACEX (01796) Enters Strategic Cooperation Agreement with Xinhua Pharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-10 19:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>METASPACEX (01796) announced that on December 10, 2025, the company signed a strategic cooperation agreement with Xinhua Pharmaceutical Development (Qianjiang) Co., Ltd.</p>\n<p>Under the agreement, both parties have initially agreed to explore collaborative opportunities in China's traditional Chinese medicine (TCM) and healthcare industry. To capitalize on policy opportunities and market growth potential in the TCM and healthcare sectors, the two companies intend to establish strategic partnerships in areas including TCM resource development, production and supply chain management, modern TCM product R&D, manufacturing, marketing, as well as capital market and industrial cooperation.</p>\n<p>The strategic cooperation aims to achieve complementary resources and synergistic development. Both parties will also engage in in-depth collaboration by integrating big data and advanced intelligent computing to focus on AI-driven standardization, modernization, and marketing of TCM.</p>\n<p>Depending on market conditions and cooperation progress, senior management meetings may be held periodically to discuss the form, direction, and other relevant matters regarding collaborative projects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01796","symbol_name":"METASPACEX","start_time":0,"source_url":"","article_id":"1124640871","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124640871","pubTimestamp":1765364775,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"METASPACEX (01796) announced that on December 10, 2025, the company signed a strategic cooperation agreement with Xinhua Pharmaceutical Development (Qianjiang) Co., Ltd. Under the agreement, both...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","01796":"METASPACEX","BK1148":"建筑与工程","BK1515":"抗疫概念","09939":"开拓药业-B","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"METASPACEX(01796)与新华制药订立战略合作协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"01796":1,"09939":1},"content_text":"METASPACEX (01796) announced that on December 10, 2025, the company signed a strategic cooperation agreement with Xinhua Pharmaceutical Development (Qianjiang) Co., Ltd.\nUnder the agreement, both parties have initially agreed to explore collaborative opportunities in China's traditional Chinese medicine (TCM) and healthcare industry. To capitalize on policy opportunities and market growth potential in the TCM and healthcare sectors, the two companies intend to establish strategic partnerships in areas including TCM resource development, production and supply chain management, modern TCM product R&D, manufacturing, marketing, as well as capital market and industrial cooperation.\nThe strategic cooperation aims to achieve complementary resources and synergistic development. Both parties will also engage in in-depth collaboration by integrating big data and advanced intelligent computing to focus on AI-driven standardization, modernization, and marketing of TCM.\nDepending on market conditions and cooperation progress, senior management meetings may be held periodically to discuss the form, direction, and other relevant matters regarding collaborative projects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124640871","isCrawlerRequest":true}